Publications by authors named "P Courbon"
Article Synopsis
- 177 Lu-PSMA-617 (LuPSMA) recently gained EMA approval for treating advanced metastatic castration-resistant prostate cancer, showing potential benefits in earlier disease stages.
- A 77-year-old patient with metastatic prostate cancer developed a rare but severe complication known as therapy-related myelodysplastic syndrome (MDS) with a specific SF3B1 mutation, just one month after his sixth treatment with LuPSMA.
- Despite showing some positive responses in tumor markers and metabolic status, the patient's quality of life was significantly impacted by the onset of MDS.
Background: Working in the ICU during the first COVID-19 wave was associated with high levels of mental health disorders.
Research Question: What are the mental health symptoms in health care providers (HCPs) facing the second wave?
Study Design And Methods: A cross-sectional study (October 30-December 1, 2020) was conducted in 16 ICUs during the second wave in France. HCPs completed the Hospital Anxiety and Depression Scale, the Impact of Event Scale-Revised (for post-traumatic stress disorder), and the Maslach Burnout Inventory.